SCHEMBL6005220

SCHEMBL6005220

Bc1ccc2c(=O)[nH]ccc2c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.53
GRM5 P41594 1/20 0.51
ROCK1 Q13464 11/20 0.45
ROCK2 O75116 6/20 0.45
PRKCD Q05655 2/20 0.45
PRKACA P17612 1/20 0.45
PRKG1 Q13976 1/20 0.45
PKN1 Q16512 1/20 0.45
PKN2 Q16513 1/20 0.45
AAK1 Q2M2I8 1/20 0.45
CDC42BPA Q5VT25 1/20 0.45
Q6ZSR9 Q6ZSR9 1/20 0.45
BMP2K Q9NSY1 1/20 0.45
CDC42BPB Q9Y5S2 1/20 0.45
PRKX P51817 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKD1 Q15139 1/20 0.41
CHEK1 O14757 1/20 0.40
MAP2K1 Q02750 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2619280 0.84 PARP1 (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL1536304 0.76 CHEK1 (0.61) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL1035426 0.76 PARP1 (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL29809657 0.76 AHR (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL4007368 0.76 PARP1 (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL25151218 0.76 PARP1 (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL1551818 0.76 AHR (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL3004637 0.76 PARP1 (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL6797681 0.76 PARP1 (0.53) PARP1GRM5ROCK1ROCK2PRKCD
SCHEMBL7588 0.76 AHR (0.53) PARP1GRM5ROCK1ROCK2PRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020244539-A1 PYRIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF 江苏恒瑞医药股份有限公司 2020-12-10 WO disclosed
WO-2020216378-A1 HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2020-10-29 WO disclosed
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP PARP1 3023/4885GRM5 106/4885ROCK1 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.